August 2026 Options Now Available For Boston Scientific (BSX)

Boston Scientific (BSX) is trading at $96.33 and Stock Options Channel highlights two actionable option strategies: a sell-to-open $85 put (bid $3.20) which nets a $81.80 cost basis and represents ~12% downside protection with a 77% probability of expiring worthless and a 3.76% yield (5.59% annualized). Alternatively, a covered call at the $100 strike (bid $7.20) would cap upside at $100 but deliver an 11.28% total return to August 2026 if called, with a 47% chance of expiring worthless and a 7.47% premium boost (11.09% annualized). Implied volatilities are ~30% (put) and 29% (call) versus a 12‑month realized volatility of 24%; the piece frames these as yield-enhancing, lower‑impact trade ideas tracked on the provider’s contract pages.

Analysis

Market structure: The option market setup makes income strategies the clear near-term winners—cash‑secured put sellers at the $85 Aug‑2026 strike receive $3.20 (net effective entry $81.80) with a modelled 77% chance of expiry worthless, while covered‑call writers at $100 collect $7.20 (11.3% capped return). Buyers of uncovered upside are disadvantaged by 29–30% IV (vs realized 24%), meaning options are pricing a premium for tail moves; market makers and volatility sellers capture that spread unless a device‑specific shock materializes.

Risk assessment: Tail risks include device recalls, adverse clinical/FDA outcomes, or material reimbursement shifts that could push IV >40% and move BSX >15% in days; these are low probability but would blow through the 77% odds. Short term (days–months) option P&L will be IV‑driven; medium term (quarters) fundamentals (earnings, procedure volumes) drive equity performance; long term (years) litigation and product pipelines determine market share.

Trade implications: Use defined‑risk income trades to monetize the IV premium—cash‑secured $85 puts and covered $100 calls through Aug‑2026 are logical yield engines if comfortable with assignment at $85/$100 levels. Cross‑asset: a systemic risk shock would widen credit spreads (hurt medtech funding) and lift USD funding costs; options sellers should monitor bond spreads and VIX as hedges.

Contrarian angle: Consensus underweights the value of collecting yield vs buying outright—implied vol > realized by ~5–6ppt suggests selling premium is underpriced risk/reward if you can accept assignment. Beware that the income trade is asymmetric: large downside (>15%) from idiosyncratic shocks can erase multi‑year returns, so coupling income sales with protective hedges or tight position sizing is essential.

Key Decisions for Investors

• Establish a 1.5–2.5% cash‑secured put position in BSX by selling Aug‑2026 $85 puts at $3.20 (effective entry $81.80). Size at most 2% of portfolio; if assigned, convert to a 2–3% long equity stake and consider selling the $100 call against shares.
• If already bullish on BSX, buy 2–3% of portfolio in BSX shares and sell Aug‑2026 $100 covered calls at $7.20 to lock an 11.3% pre‑tax capped return; set a hard stop‑loss at 12% below purchase or roll the call if BSX >$105 by expiry to avoid assignment.
• If preferring relative risk, implement a 1.5% long BSX vs 1% short IHI (iShares U.S. Medical Devices ETF) pair to express stock‑specific upside while hedging sector cyclicality; rebalance monthly and trim if spread narrows under 3%.
• Risk control: if BSX IV rises above 40% or credit spreads widen (BofA MOVE >120 or CDX spreads +25bp), reduce option‑selling size by 50% and buy 1:1 monthlies (calendar) protection or purchase 0.5% portfolio put protection at 10–15% OTM.